Prof Philip MacCarthy (King's College Hospital, London, UK) discusses whether transcatheter aortic valve implantation (TAVI) should be the default treatment for patients with symptomatic aortic stenosis and reviews how and when TAVI should be used in selected patients.
1. BCIS has recently released a consensus statement on TAVI that you are an author of, what compelled you/BCIS to do so?
2. Please summarise the key recommendations; does this reflect all approved valves?
3. Has TAVI evolved to become the default treatment for patients with symptomatic AS? If not, what more is needed to convince you?
4. In which clinical settings would a patient not be a candidate for TAVI and how do you assess this?
5. Does the durability of TAVI still need to be assessed alongside factors such as coronary obstruction, longer term?
Filmed in London at BCIS ACI 2020.
Interviewer: Leiah Norcott
Videographer: Natacha Wienand / Dominic Woodruff